MedTrace Logo

DAS181 for Severe COVID-19: Compassionate Use

NCT04324489 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-05-05

No results posted yet for this study

Summary

The objective of the study is to investigate the safety and potential efficacy of DAS181 for the treatment of severe COVID-19.

Conditions

Interventions

DRUG

DAS181

Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.

Sponsors & Collaborators

  • Ansun Biopharma, Inc.

    collaborator INDUSTRY

  • Renmin Hospital of Wuhan University

    lead OTHER

Principal Investigators

  • Zuojiong Gong, MD · Renmin Hospital of Wuhan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-06
Primary Completion
2020-04-16
Completion
2020-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04324489 on ClinicalTrials.gov